Welcome

Investor Relations

Corporate Profile

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Latest Investor Presentation Latest Earnings Presentation
(Updated September 9, 2021) (Updated November 4, 2021)
Stock Information
NASDAQNVAX
NASDAQNVAX
Recent News
Jan 19, 2022
Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for Novavax COVID-19 Vaccine

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Australia's...

Jan 12, 2022
South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited, a...

Jan 10, 2022
Novavax and Serum Institute of India File for Emergency Use Authorization of Novavax' COVID-19 Vaccine in South Africa

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd....

View All Press Releases

Events
Novavax to Participate in the 40th Annual J.P. Morgan Healthcare Conference
Monday, January 10, 2022
9:00am - 9:40am EST
Novavax Update Conference Call and Webcast
Wednesday, December 22, 2021
4:30pm - 5:00pm EST
Evercore ISI’s 4th Annual HealthCONx Virtual Conference
Thursday, December 2, 2021
9:15am - 9:35am EST

View All Events